Neurocrine Biosciences
NBIX
408 hedge funds and large institutions have $8.86B invested in Neurocrine Biosciences in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 167 increasing their positions, 131 reducing their positions, and 54 closing their positions.
54% more call options, than puts
Call options by funds: $83.8M | Put options by funds: $54.6M
27% more repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 131
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less capital invested
Capital invested by funds: $9.23B → $8.86B (-$369M)
3% less funds holding
Funds holding: 419 → 408 (-11)
4.59% less ownership
Funds ownership: 101.28% → 96.7% (-4.6%)
11% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$39.9M |
| 2 |
HM
HealthCor Management
New York
|
+$37.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$36.9M |
| 4 |
Morgan Stanley
New York
|
+$22.9M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$19.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$275M |
| 2 |
BlackRock
New York
|
-$81.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$44.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$43.7M |
NBIX Hedge Fund Activity: Q2 2021 in Review
408 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2021, worth a combined $8.86B — down 4% from $9.23B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of NBIX and 48 opened new positions — a net loss of 6 holders — while 131 trimmed existing stakes and 167 added.
The largest buyer was Eaton Vance Management, adding an estimated $39.9M. The largest seller was Fidelity Investments, cutting an estimated $275M.
- 408 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2021, down from 419 in Q1 2021.
- Funds reported $8.86B of Neurocrine Biosciences stock for Q2 2021, down 4% quarter-over-quarter.
- 48 funds opened new Neurocrine Biosciences positions in Q2 2021 and 54 closed out, a net change of -6 holders.
- The largest Neurocrine Biosciences buyer in Q2 2021 was Eaton Vance Management, an estimated $39.9M added.
- The largest Neurocrine Biosciences seller in Q2 2021 was Fidelity Investments, an estimated $275M sold.
Based on aggregated 13F filings for Q2 2021.